[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Nektar Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"H Scott Boswell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ H Scott Boswell","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ H Scott Boswell"}]

Find Clinical Drug Pipeline Developments & Deals for Mivavotinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : In a retrospective analysis of prior phase 1/2 studies in patients with DLBCL, patients with non-GCB DLBCL who received CB-659 (mivavotinib) had a response rate of 53%, as compared to a response rate of 22% in patients with GCB DLBCL.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Mivavotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 08, 2022

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 06, 2019

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : H Scott Boswell

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 11, 2018

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Nektar Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 02, 2017

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 30, 2017

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 03, 2017

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 21, 2017

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 03, 2016

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : TAK-659 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Triple Negative Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 15, 2016

                          Lead Product(s) : Mivavotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank